219 related articles for article (PubMed ID: 35697870)
1. The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors.
Bailey S; Mhango G; Lin JJ
Osteoporos Int; 2022 Sep; 33(9):1989-1997. PubMed ID: 35697870
[TBL] [Abstract][Full Text] [Related]
2. Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy Is Associated With Decreased Fractures in Women With Breast Cancer.
Lu H; Lei X; Zhao H; Elting L; Siricilla M; Ursani MA; Giordano SH; Suarez-Almazor M
J Bone Miner Res; 2021 May; 36(5):861-871. PubMed ID: 33484602
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
Kwan ML; Lo JC; Laurent CA; Roh JM; Tang L; Ambrosone CB; Kushi LH; Quesenberry CP; Yao S
J Cancer Surviv; 2023 Feb; 17(1):139-149. PubMed ID: 33565036
[TBL] [Abstract][Full Text] [Related]
4. Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors.
Stratton J; Hu X; Soulos PR; Davidoff AJ; Pusztai L; Gross CP; Mougalian SS
J Oncol Pract; 2017 May; 13(5):e505-e515. PubMed ID: 28267392
[TBL] [Abstract][Full Text] [Related]
5. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
8. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
Oncologist; 2019 Nov; 24(11):1432-1438. PubMed ID: 31292269
[TBL] [Abstract][Full Text] [Related]
9. Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab.
Catalano A; Gaudio A; Morabito N; Basile G; Agostino RM; Xourafa A; Atteritano M; Morini E; Natale G; Lasco A
J Endocrinol Invest; 2017 Aug; 40(8):851-857. PubMed ID: 28332172
[TBL] [Abstract][Full Text] [Related]
10. Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors.
Catalano A; Gaudio A; Agostino RM; Morabito N; Bellone F; Lasco A
J Endocrinol Invest; 2019 Nov; 42(11):1337-1343. PubMed ID: 31127591
[TBL] [Abstract][Full Text] [Related]
11. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
Pedersini R; Amoroso V; Maffezzoni F; Gallo F; Turla A; Monteverdi S; Ardine M; Ravanelli M; Vassalli L; Rodella F; Formenti AM; Dalla Volta A; Simoncini EL; Giustina A; Maroldi R; Berruti A
JAMA Netw Open; 2019 Sep; 2(9):e1911080. PubMed ID: 31560383
[TBL] [Abstract][Full Text] [Related]
12. Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density.
Nunes FAP; de Farias MLF; Oliveira FP; Vieira L; Lima LFC; de Paula Paranhos F; de Mendonça LMC; Madeira M
Arch Endocrinol Metab; 2021 Nov; 65(4):505-511. PubMed ID: 34283901
[TBL] [Abstract][Full Text] [Related]
13. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
Sowa PM; Downes MJ; Gordon LG
J Bone Miner Metab; 2017 Mar; 35(2):199-208. PubMed ID: 26969395
[TBL] [Abstract][Full Text] [Related]
15. Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy: A descriptive study.
Baatjes KJ; Kotze MJ; McCaul M; Conradie M
PLoS One; 2019; 14(4):e0214153. PubMed ID: 30939140
[TBL] [Abstract][Full Text] [Related]
16. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
Hamood R; Hamood H; Merhasin I; Keinan-Boker L
Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
[TBL] [Abstract][Full Text] [Related]
17. Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors.
Catalano A; Morabito N; Agostino RM; Basile G; Gaudio A; Atteritano M; Natale G; Xourafa A; Morini E; Adamo V; Lasco A
Menopause; 2017 Jan; 24(1):85-91. PubMed ID: 27575547
[TBL] [Abstract][Full Text] [Related]
18. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
[TBL] [Abstract][Full Text] [Related]
19. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
[TBL] [Abstract][Full Text] [Related]
20. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial.
Kilbreath S; Refshauge KM; Beith J; Ward L; Sawkins K; Paterson R; Clifton-Bligh P; Sambrook PN; Simpson JM; Nery L
Contemp Clin Trials; 2011 Sep; 32(5):704-9. PubMed ID: 21570487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]